WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 863 - Thirty-fourth Report
(1996; 200 pages) View the PDF document
Table of Contents
View the document1. Introduction
Open this folder and view contents2. The international pharmacopoeia and related activities
View the document3. Simple test methodology
Open this folder and view contents4. Stability of dosage forms
Open this folder and view contents5. Good manufacturing practices for pharmaceutical products
Open this folder and view contents6. Legal and administrative aspects of the functioning of national drug regulatory authorities
Open this folder and view contents7. Quality assurance in the supply system
View the document8. Terminology
View the documentAcknowledgements
View the documentReferences
Open this folder and view contentsAnnex 1 - Guidelines for the graphic representation of chemical formulae
View the documentAnnex 2 - List of available International Chemical Reference Substances1
View the documentAnnex 3 - List of available International Infrared Reference Spectra
Close this folderAnnex 4 - General recommendations for the preparation and use of infrared spectra in pharmaceutical analysis
View the document1. Introduction
View the document2. Apparatus
View the document3. Method of verification of frequency scale and resolution
View the document4. Environment
View the document5. Use of solvents
View the document6. Preparation of the substance to be examined
View the document7. Identification by reference substance
View the document8. Identification by reference spectrum
View the document9. Reflectance techniques
Open this folder and view contentsAnnex 5 - Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms
Open this folder and view contentsAnnex 6 - Good manufacturing practices: guidelines on the validation of manufacturing processes
Open this folder and view contentsAnnex 7 - Good manufacturing practices: supplementary guidelines for the manufacture of investigational pharmaceutical products for clinical trials in humans
Open this folder and view contentsAnnex 8 - Good manufacturing practices: supplementary guidelines for the manufacture of herbal medicinal products1
Open this folder and view contentsAnnex 9 - Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability
Open this folder and view contentsAnnex 10 - Guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce
Open this folder and view contentsAnnex 11 - Guidelines for the assessment of herbal medicines1,2
Open this folder and view contentsAnnex 12 - Guidelines on import procedures for pharmaceutical products
View the documentBack Cover
 

2. Apparatus

Conventional infrared spectrometers disperse the infrared radiation by means of either gratings or prisms. The development of computerized laboratory equipment provides the additional option of using an interferometer coupled to a computer for the reduction of the data, by performing a Fourier transformation of the interferogram, to generate an infrared spectrum. These instruments are called Fourier transform infrared spectrometers (FTIRs). Apart from small differences in the low-frequency cut-off, all of the above types of infrared instruments generate comparable data and can generally be used interchangeably for qualitative analyses. However, each instrument will possess specific signal-to-noise and resolution characteristics.

Spectrophotometers suitable for use for identification tests should normally operate in the range 4000-600 cm-1 (2.5-16.7 µm) or in some cases up to 250 cm-1 (40 µm). If the attenuated total reflectance technique is to be used, the instrument must be equipped with a suitable attachment consisting of a single or multireflecting element. The attachment and a suitable mounting should permit its alignment in the spectrophotometer for maximum transmission.

to previous section to next section
 

Last updated: May 3, 2013